Start 30 days free, no card. Full Pro access for a month, then decide. Start free

Back to analysts list

Analyst

Jason Wittes

ROTH Capital Partners · covers Healthcare

Period: Reporting period mapped to calendar 2025 Q2.

Limited coverage. Only 1 question of coverage. Treat these numbers as directional — sample too small for reliable averages.
Questions
1on tracked calls
Challenge rate
0%none of 1 questionLimited sample
Companies
1questioned at least once
Reporting periods
1with questions

These figures cover the whole profile: every tracked question, all reporting periods.

How to read these numbers

Challenge rate is the share of questions that pushed back, pressed for specifics or questioned management’s assumptions. It describes how questions were asked on the calls tracked here; it does not measure whether any view turned out to be right.

Rounding. Rates are rounded to whole percentages, so a small share can show as 0% even when some questions were challenging. The count beside each rate is exact; “none of N questions” means no question was challenging.

No questions recorded. “—” means there is nothing to calculate: no questions were recorded for that period on the calls tracked here. It does not mean there was no activity.

Fewer than 3 questions. A company-level rate is withheld when fewer than 3 questions were recorded for that company; the questions are still counted everywhere else.

Small samples. Profiles with fewer than 10 questions are marked Limited sample.

Reporting periods. Questions are grouped by the calendar quarter each company’s fiscal reporting period maps to, not by the date of the call. Periods without a calendar mapping are listed separately under their fiscal label.

Questions asked

Grouped by company, most questions first. Open a company to read its questions, newest reporting period first.

Showing 1 of 1 question from 1 company

ZBHZimmer Biomet1 question · 1 reporting period · 0 of 1 challenging
ZBH company page →

Calendar 2025 Q2

do you think it gives you a pretty strong position to maintain both in terms of their cutting and their AI applications

Innovation & R&DM&ATranscript · FY2025 Q2 →
Show response

Ivan described three benefits of autonomous robotics: precision without human deviation, reduced cognitive load/surgeon fatigue, and seamless CVH ecosystem integration. mBôs features include 7-degree-of-freedom arm, markerless tracking, CT-based planning, AI/ML personalization, and remote surgery capability. Semi-autonomous launch early 2027.

Challenge rate by company

Every company this analyst questioned, most questions first. A company-level rate is shown from 3 questions; below that it is withheld.

CompanyQuestionsChallenge rate
ZBH Zimmer Biomet1—Rate withheld: fewer than 3 questions
  • ZBH
    Zimmer Biomet · 1 question
    —rate withheld: under 3 questions

Activity by reporting period

Questions recorded for each calendar quarter that companies’ reporting periods map to (not the call date), with the challenge rate for that period. Periods inside the range with no questions are shown as “No questions recorded”.

Questions by calendar reporting period
Calendar periodQuestionsChallenge rateCompanies
2025 Q210%none of 1 question1
  1. 2025 Q21 question · challenge rate 0% (none of 1 question) · 1 company

Topics

Topics tagged on this analyst’s questions.

  • Innovation & R&D1
  • M&A1